Pharma major Ranbaxy Laboratories today said it has restarted production of generic cholesterol lowering drug Atorvastatin as it looks to resume supplies to the American market.
In November last year
Ranbaxy Laboratories has stopped production of its generic version of cholesterol lowering drug Lipitor until it investigates the issue of potential glass particles in certain lots, the US health regulator
Drugmakers Ind-Swift and Wockhardt have jointly launched a generic version of Pfizer's cholesterol lowering drug Lipitor in the United Kingdom, the two companies said.
The copycat version was launched on
Pfizer and Ranbaxy Laboratories have been sued in an anti-trust case filed in federal court in New York alleging the drugmakers engaged in an anti-competitive scheme to delay a generic
Refuting claims of possible failure to launch generic Caduet Ranbaxy Laboratories on Friday said the launch would happen soon.
Ranbaxy Laboratories said on Thursday it has launched the first generic version of the cholesterol-lowering Lipitor in the US, the largest selling drug of all time, sending its shares surging
The US Food and Drug Administration confirmed on Wednesday that it had given approval to Ranbaxy Laboratories to make the first generic version of the cholesterol-lowering drug Lipitor.
Come Wednesday and Daiichi Sankyo-owned Ranbaxy, as per its June 2008 agreement, will have the licence to sell generic versions of Lipitor (Atorvastatin) in the United States, a drug meant
Stay informed on our latest news!
